Scil Proteins, a German private biotech company specialising in the research, development and production of recombinant proteins, has appointed Ulrich Haupts as its new chief scientific officer. As of 1 October, he will replace Arnd Steuernagel.
Haupts was previously director of protein optimisation at Bayer Healthcare, a position he has held for the last three years. Prior to that, he spent seven years at Direvo Biotech (which was subsequently acquired by Bayer Schering Pharma in 2008) as department head of assay development and later, as vp of r&d biopharmaceuticals.
Dr Haupts also worked for three years at SmithKline Beecham UK in the New Assay Technology group.
Scil Proteins appoints chief scientific officer
Ulrich Haupts joins the biotech firm from Bayer Healthcare
You may also like
Drug Delivery
Bio-Sourcing and Zerion Pharma secure Eurostars funding to develop HER2 oral monoclonal antibody
The pair have been awarded a €1.3m Eurostars grant to develop an oral formulation of the anti-HER2 monoclonal antibody trastuzumab for breast cancer, combining Bio-Sourcing’s BioMilk platform with Zerion’s Dispersome technology to advance the candidate through preclinical development
Research & Development
FairJourney Bio launches cryo-EM services to support antibody discovery and biologics design
The new offering at the company's San Diego laboratories provides high-resolution structural insights to accelerate antibody discovery, selection and optimisation across the biologics R&D pipeline
Research & Development
Studies on HIV and TB reveal tradeoffs for both viruses and immune system in race to survive
Research teams have identified mechanisms by which HIV can evade lenacapavir, at the cost of the virus's reproduction and how the immune system can use bacteria to protect against infection — until TB evolved to take advantage